Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2017-05-02
2018-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In mid-1980s, a new marker of myocardial damage was proposed, namely: fatty-acid-binding protein (FABP). However, the diagnostic value of FABP cannot be interpreted unambiguously because of insufficient number of studies determining the sensitivity and specificity of the test in various manifestations of acute coronary syndrome (ACS).
Available literature presents a wide range of reference values of FABP for MI diagnosis. Reference value ranges are proposed by manufacturers of diagnostic kits based on previous studies. In addition, there is no information about the FABP changes during the first three hours of the disease, as well as there are no data on diagnostic value of changes in this indicator ("∆") in patients with ACS without ST-segment elevation. These considerations provide rationale and support novelty of the planned pilot study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Higher Cut-off Values to Diagnose Acute Myocardial Infarction in Patients With Elevated Hs-cTnT Concentrations
NCT06059079
Initial CT Perfusion-Guided Strategy for Suspected NSTEMI
NCT06689267
Induced Myocardial Ischemia: a Serial Troponin T and Troponin I Measurements
NCT03203057
Hs-cTnI Diagnosis of NSTE-ACS Patients in China
NCT03734796
Troponin POCT in the Diagnosis of an Acute Myocardial Infarction
NCT03400553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Physical examination (at baseline) and monitoring of vital signs (blood pressure, heart rate, breathing rate) at hours 1, 2, and 3 after admission to hospital.
2. Registration of 12-lead electrocardiogram (ECG) (at baseline, after 24 hours, and at the day of discharge).
3. At baseline (at the time of admission to hospital), venous blood will be obtained to perform blood tests for determination of troponin I, FABP, and CPK-MB levels. At the same time, venous blood will be sampled for routine clinical laboratory blood tests. At hours 1, 2, and 3 after admission to hospital, venous blood will be sampled for assessment of the troponin I and FABP levels.
4. Echocardiography will be performed 24 hours after admission (LVEDV, LVESV, and EF). At day 3, standard echocardiography will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FABP group
Coronary angiography and PCI (according to indications).
FABP
Assessment of changes in FABP concentrations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FABP
Assessment of changes in FABP concentrations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male patients
* Acute pain in the chest similar to myocardial infarction with/or without ECG changes
* Admission to the hospital within 4 hours from onset of the disease.
Exclusion Criteria
* Cerebral blood circulation disorder
* Recent surgical intervention
* Extensive burns of degree 2-3
* Massive wounds and injuries
* Percutaneous coronary intervention or cardioversion
* Pregnancy or lactation
* Malignant tumors of stage 4
* Severe renal insufficiency (GFR\< 30 mL/min)
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tomsk National Research Medical Center of the Russian Academy of Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vyacheslav V. Ryabov, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Cardiology Research Institute, Tomsk NRMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Research Institute, Tomsk NRMC
Tomsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FABP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.